Evidence map›Paper›PMID 38529277›Full record

Observational studyFrontiers in immunology2024

Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19.

Daisuke Kasugai, Taku Tanaka, Takako Suzuki, Yoshinori Ito, Kazuki Nishida, Masayuki Ozaki, Takeo Kutsuna, Toshiki Yokoyama, Hitoshi Kaneko, Ryo Ogata and 12 more

Open access · goldAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 1 country.

Daisuke KasugaiDepartment of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Taku TanakaDepartment of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takako SuzukiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshinori ItoDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuki NishidaDepartment of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masayuki OzakiDepartment of Critical Care Medicine, Komaki City Hospital, Komaki, Japan.
Takeo KutsunaDepartment of Respiratory Medicine, Daido Hospital, Nagoya, Japan.
Toshiki YokoyamaDepartment of Emergency and Critical Care Medicine, Tosei General Hospital, Seto, Japan.
Hitoshi KanekoDepartment of Emergency and Critical Care Medicine, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Ryo OgataDepartment of Respiratory Medicine, Meitetsu Hospital, Nagoya, Japan.
Ryohei MatsuiDepartment of Emergency and Critical Care Medicine, Nagoya City University Hospital, Nagoya, Japan.
Takahiro GoshimaDepartment of Emergency and General Internal Medicine, Fujita Health University, Toyoake, Japan.
Hiroshi HamadaDepartment of Internal Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Azusa IshiiDepartment of Respiratory Medicine, Chukyo Hospital, Nagoya, Japan.
Yusuke KodamaDepartment of Internal Medicine, Kyoritsu General Hospital, Nagoya, Japan.
Naruhiro JingushiDepartment of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ken IshikuraDepartment of Emergency and Disaster Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
Ryo KamidaniDepartment of Emergency and Critical Care Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Masashi TadaDepartment of Internal Medicine, SaiShukan Hospital, Kitanagoya, Japan.
Hideshi OkadaDepartment of Emergency and Critical Care Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Takanori YamamotoDepartment of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yukari GotoDepartment of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPGifu University · JPChukyo Hospital · JPDaido University · JPFujita Health University · JPIwaki Kyoritsu General Hospital · JPKomaki City Hospital · JPMeitetsu Hospital · JPMie University · JPNagoya City University Hospital · JPNagoya Ekisaikai Hospital · JPNational Hospital Organization · JPTokyo Metropolitan Tama Medical Center · JPTosei General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronavirus disease 2019 (COVID-19) features a hypercoagulable state, but therapeutic anticoagulation effectiveness varies with disease severity. We aimed to evaluate the dynamics of the coagulation profile and its association with COVID-19 severity, outcomes, and biomarker trajectories. Methods: This multicenter, prospective, observational study included patients with COVID-19 requiring respiratory support. Rotational thromboelastometry findings were evaluated for coagulation and fibrinolysis status. Hypercoagulable status was defined as supranormal range of maximum clot elasticity in an external pathway. Longitudinal laboratory parameters were collected to characterize the coagulation phenotype. Results: Of 166 patients, 90 (54%) were severely ill at inclusion (invasive mechanical ventilation, 84; extracorporeal membrane oxygenation, 6). Higher maximum elasticity ( Conclusions: While hypercoagulable states become more evident with increasing severity of respiratory disease in patients with COVID-19, normocoagulable phenotype is associated with triggered by alternative pathway activation and poor outcomes.

Indexed as

COVID-19ThrombophiliaBlood CoagulationHumansPhenotypeProspective Studiesalternative complement pathwayblood coagulation disordersCOVID-19microthrombosisrotational thromboelastometry

Identifiers

PMID38529277
PMCPMC10961343
OpenAlexW4392657983

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.